Navigation Links
Addiction in Medical Technology

Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians

... potential tragedies, of prescription chemical addiction and abuse are being discussed, these articles offer crucial overview, direction and optimism. addiction to and abuse of prescription opioid drugs are ... Keen awareness by family and friends of potential addiction is crucial for physicians and other health care ...

Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief

... that these medicines have the likelihood of an addiction similar to smoking marijuana, leading researchers ... should be studied further. Using the addiction Research Center Inventory (ARCI), the ... psychoactive properties and suggestive of an addiction potential." Poster Session Information ...

Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial

... 180 patients have now been enrolled at 11 leading addiction research facilities across the United States. ... represents an outstanding accomplishment for the addiction field," said Eugene Somoza, M.D., Ph.D., Director, Cincinnati addiction Research Center, and Coordinating ...

Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction

... prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today ... methamphetamine addicted patients at 15 leading addiction treatment clinical centers in the United States. ... treatment for cocaine and methamphetamine addiction in two pilot studies and one Phase II ...

Arizona Doctor Offers New Addiction Drug Treatment for Meth Addicts Showing More Than 60% Success Rate

... has identified a very promising new addiction treatment option that shows high success rates ... meth, there is a mandate to raise awareness about addiction treatment. Ellison's PROMETA(R) 30-day program ... number of Arizonians seeking treatment for meth addiction quintupling between 2000 and 2004, out-patient ...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results

... trial for methamphetamine addiction in second quarter of 2008 CORAL GABLES, Fla., ... discussed in Newsweek magazine's cover article on addiction in the March 3, 2008 issue. In the article, one of the foremost experts in the field of addiction noted that the results of this trial provide the ...

Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award

... has advanced the scientific knowledge of addiction recovery. (Logo: ... honorarium in May at the National Association of addiction Treatment Providers (NAATP) annual conference. ... the interdisciplinary approach to addiction treatment that has been replicated worldwide. ...

Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction

... improve abstinence achievement rates of behavioral therapy administered by addiction treatment specialists, and reduce recidivism. We have worked diligently ... evidence that CPP-109 is safe and effective for the treatment of cocaine addiction and methamphetamine addiction, the Company's ability to protect its ...

Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months

... and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. The final 12-month data confirm the highly ... investigational vaccine being developed by Nabi to treat nicotine addiction and prevent smoking relapse. NicVAX(R) is designed to stimulate the immune ...

September is National Pain Awareness Month

... synthetic form of a naturally occurring peptide, circumvents concerns over addiction and safety linked to opioid use. "Chronic pain disrupts an individual's ... It saves you from being exposed to narcotics and you don't develop an addiction or tolerance to it." Additionally, there are no withdrawal symptoms and ...

Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month

... local Detroit-area community leaders are hosting a public forum to discuss addiction treatment options and resources for help. The forum will feature ... forum and take this opportunity to give a local voice to the problem of addiction and the recovery solution in Michigan. The forum will also spotlight the ...

Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months

... and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. These nine-month data demonstrate NicVAX ... investigational vaccine being developed by Nabi to treat nicotine addiction and prevent smoking relapse. NicVAX is designed to stimulate the immune ...

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

... extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in ...

Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009

... extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in ...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

... Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive-compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents in ...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

... pressure. NUCYNTA(TM) is a mu-opioid agonist and is a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addiction disorders. Diversion of Schedule II products is an act subject to criminal penalty. NUCYNTA(TM) can be abused in a manner similar to other ...

One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials

... addictions, and new treatment options are desperately needed," said Elliot Ehrich, M.D., chief medical officer of Alkermes. "We believe that the addiction field will evolve in a similar way to other CNS markets, such as mental illnesses, where treatments include both oral and injectable medications. ...

Methadone Frequently Causes Menopausal Symptoms in Young Women

... deadly, heart rate and blood pressure increases. Depression and fatigue from methadone withdrawal frequently lasts a year, without effective addiction treatment. Depression, fatigue, anxiety, and insomnia, caused by methadone often decrease rapidly, with bioidentical hormone replacement. Bone ...

Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study

... extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in ...

Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia

... or next day hangover effects that are commonly associated with other sleep medications. ITI-007 is expected to have a strong safety profile with no addiction liability. This compound is being evaluated for the treatment of sleep disorders in various patient populations with sleep maintenance problems and ...

Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain

... species. In contrast to currently marketed opioids, CR845 did not produce inhibition of intestinal transit (ileus) or elicit signs of abuse or addiction liability in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity. About Cara Therapeutics Cara ...

Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback

... extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in ...

Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss

... Partners, Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for eleven patents ...

Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845

... anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing, or elicit signs of addiction in animal models. CR845 and related compounds are covered by a recently issued U.S. patent. About Cara Therapeutics Cara Therapeutics is a ...

After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008

... extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research and manufacturing facilities in Massachusetts and Ohio. This press ...

Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight

... extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research and manufacturing facilities in Massachusetts and Ohio. This press ...

Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains

... in vaccinology. Anti-Smoking Vaccine Keeps Nicotine from Brain Among the novel vaccines to be discussed at the conference is one aimed at curbing addiction to nicotine. Scientists from Nabi Biopharmaceuticals of Rockville, MD will report data showing that their experimental vaccine, NicVAX, induces ...

Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845

... subcutaneous, or oral administration. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus) or elicit signs of addiction in animal models. Preclinical studies also indicate that CR845 possesses anti-itch activity. About Cara Therapeutics Cara Therapeutics is a ...

HealthMedia's Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships

... won a silver eHealthcare Leadership award for Best Care/Disease Management Site. MORE's online content delivers continuing care that supports addiction recovery. Ann Arbor SPARK's FastTrack award was presented to HealthMedia in recognition of the company's sustained and continued growth as well as ...

Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia

... next-day hangover effects that are commonly associated with other sleep medications. ITI-722 is expected to have a strong safety profile with no addiction liability. This compound is being evaluated for the treatment of sleep disorders in various patient populations with sleep maintenance problems and ...

NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia

... be able to avoid the systemic side effects of anti-convulsants, anti-depressants and opioids, including sedation and the potential for abuse and addiction associated with some of these drugs. NGX-4010 is administered in a physician's office in a non-invasive process that involves pre-treating the ...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

... the use of CPP-109 for the treatment of cocaine addiction and methamphetamine addiction. The CPP-109 ... Phase II clinical trial with respect to cocaine addiction in the second quarter of 2007 and our U.S. Phase II clinical trial with respect to methamphetamine addiction in the third quarter of 2007." About The ...

Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29

... rationale for the continued expansion of our addiction franchise," stated Elliot Ehrich, chief medical ... such as central nervous system disorders, addiction and diabetes. Alkermes' headquarters are ... but not limited to statements about Alkermes' addiction portfolio, including its development activities ...

NIDA Study Identifies Genes That Might Help Some People Abstain from Smoking

... researchers a step closer toward tailoring individualized drug therapy for addiction based on an individual's unique genetic make-up. "This research marks ... Nora D. Volkow. "It marks a movement from identifying the genetics of addiction vulnerability to identifying the genetic basis of successful abstinence. ...

Waismann Method Survey Reveals Dependency Risk for People Using Suboxone

... a new one," said Waismann. "Rather than write prescriptions, the addiction community should direct their efforts towards helping patients understand ... is not part of recovery. In addition, the antiquated notion that addiction is an incurable disease and belief that 'once an addict, always an ...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

... (1st line), insulinized patients, dyslipidemia or atherosclerosis. Another field of potential use of CB1 antagonists lies in neuroscience, such as addiction and cognitive disorders. These results and more were found in a search conducted by La Merie Business Intelligence. The competitor analysis of CB1 ...

Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter

... -- Thyroid deficiency and mental health -- Depression in China -- Williams syndrome in Japan and America -- Readiness for addiction treatment -- A doctor discusses: The importance of breakfast for children The Harvard Mental Health Letter is available from ...

Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron

... and COPEGUS are: -- Risks to pregnancies -- Mental health problems (such as irritability, depression, anxiety, aggressiveness, trouble with drug addiction or overdose, thoughts about suicide, suicide attempts, suicide and thoughts about homicide) -- Blood problems (like a drop in blood cells leading ...

Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''

... and COPEGUS are: -- Risks to pregnancies -- Mental health problems (such as irritability, depression, anxiety, aggressiveness, trouble with drug addiction or overdose, thoughts about suicide, suicide attempts, suicide and thoughts about homicide) -- Blood problems (like a drop in blood cells leading ...
Other Contents
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
(Date:5/22/2015)... Hershey, Pa. (PRWEB) May 22, 2015 ... has been selected to participate in the 2015 Congress ... event is described as a gathering of “America’s highest ... about new areas of healthcare, set new goals and ... will include a live surgery, during which we can ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Hands ... that June 17, 2015, the Annual One Day Sale ... Since 2007, Hands On HCMT offers drastically reduced certificates one ... and estheticians have enough sessions, through what used to be ... is wonderful for the community as well. This once a ...
(Date:5/22/2015)... May 22, 2015 Family, friends, students, ... world-renowned surgical oncologist, Dr. LaSalle D. Leffall, on Monday, ... luncheon began after Grand Rounds in the hospital’s Tower ... anxiously outside the auditorium, trying to keep the secret. ... if he sees me, he’ll know something is up,” ...
(Date:5/22/2015)... May 22, 2015 Coordinating care ... difficult process. Historically providers have not been reimbursed ... Starting in 2015, Medicare has paved the way ... Thanks to the launch of Oculus Health ... health systems using the platform will now be ...
(Date:5/22/2015)... According to a new Aegis Living Study ... as likely to worry about what will happen to their ... Boomers, 69% Silent Generation), which may help explain why nearly ... aging, particularly Millennials (47%), Gen X’ers (51%), and Boomers (43%). ... 2015 among more than 2,000 U.S. adults ages 18+. ...
Breaking Medicine News(10 mins):Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
Other TagsOther Tags